Shots:

• Genevant is eligible to receive ~$303M up front and milestone along with royalties on future product sales
• Takeda gets exclusive rights to use Genevant’s LNP technology for the development and commercialization of specified nonviral gene therapies for up to two undisclosed rare liver diseases
• The collaboration follows the initial 2021 agreement in which companies collaborated to develop nucleic acid therapeutics directed to specified targets in hepatic stellate cells to treat liver fibrosis

Click here  | Ref: Genevant Sciences | Image: Genevant Sciences